UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
August 16, 2024 10:55 ET
|
BiomX
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
August 15, 2024 06:30 ET
|
BiomX
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company’s leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting...
BiomX Inc. Announces 1-for-10 Reverse Stock Split
August 15, 2024 06:30 ET
|
BiomX
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
August 08, 2024 07:00 ET
|
BiomX
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
July 29, 2024 07:00 ET
|
BiomX
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
July 10, 2024 06:30 ET
|
BiomX
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
May 30, 2024 16:50 ET
|
BiomX
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
May 30, 2024 07:00 ET
|
BiomX
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
May 21, 2024 06:30 ET
|
BiomX
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a...
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
May 15, 2024 07:00 ET
|
BiomX
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...